Merck 2010 Annual Report Download - page 61


Therapeutic area Compound Indication Status
Oncology Erbitux ® (cetuximab, monoclonal anti-
EGFR antibody) 1
Adjuvant colorectal cancer 2Phase III
Gastric cancer Phase III
Cilengitide (integrin inhibitor) Glioblastoma (brain tumor) Phase III
Stimuvax ® (cancer immunotherapy) 3Non-small cell lung cancer (NSCLC) Phase III
Erbitux ® Breast cancer Phase II
Cilengitide Head and neck cancer (SCCHN) Phase II
Non-small cell lung cancer (NSCLC) Phase II
Monoclonal anti-integrin
antibody (DI17E6)
Colorectal cancer Phase II
TLR9 immunomodulator (IMO−2055) 4Head and neck cancer (SCCHN) Phase II
MEK inhibitor (AS703026/
MSC1936369B)
Solid tumors and hematological diseases Phase I
c-Met kinase inhibitors
(EMD1214063, EMD1204831) 5
Solid tumors Phase I
Neurodegenerative
Diseases
Serum-free formulation of Rebif ® Relapsing-remitting forms of
multiple sclerosis (MS)
USA: applica-
tion submitted
Clinically isolated syndrome (CIS) Phase III
Cladribine tablets Relapsing-remitting forms of MS;
Russia and Australia: approved,
USA: application submitted 6
Approved/
applications
submitted
Clinically isolated syndrome (CIS) Phase III
Safinamide 7 Early-stage Parkinson’s disease Phase III
Mid- to late-stage Parkinson’s disease Phase III
Immune-tolerizing agent
(ATX-MS-1467) 8
Relapsing-remitting forms of MS Phase I
Extended-release formulation of
interferon beta-1a 9
Relapsing-remitting forms of MS Phase I
Rheumatology Atacicept (anti-BLyS/anti-APRIL
fusion protein) 10
Systemic lupus erythematosus (SLE) Phase III
Fibroblast growth factor 18 10 Cartilage injury Phase II
Osteoarthritis Phase I
Endocrinology Long-acting growth hormone
(ARX 201) 11
Growth hormone deficiency Phase II
1 Developed in cooperation with ImClone LLC: Erbitux ® is a
trademark of ImClone LLC, a wholly owned
subsidiary of Eli Lilly & Co.
2 Sponsored and coordinated by the Fédération Francophone
de Cancérologie Digestive (FFCD)
3 Exclusive worldwide licensing rights acquired from
Oncothyreon Inc.
4 In-licensed from Idera Pharmaceuticals, Inc.
5 Collaboration with M. D. Anderson Cancer Center
6 CHMP adopted a final negative opinion on the marketing
authorization application in the EU in January 2011
7 Collaboration with Newron Pharmaceuticals S.p.A.
8 Collaboration with Apitope Technology (Bristol) Ltd.
9 Collaboration with Flamel Technologies S.A.
10
In-licensed from ZymoGenetics, Inc., a wholly owned sub-
sidiary of Bristol-Myers Squibb Company
11 Collaboration with Ambrx, Inc.
NSCLC: Non-small cell lung cancer
SCCHN: Squamous cell carcinoma of the head and neck
CIS: Clinically isolated syndrome
Company 57Management Report Corporate governance Consolidated Financial Statements More information
Merck Serono